Biological
Japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated) clinical trials
Also written IC51 and IXIARO.
- studies test it
- 18
- open now
- 1
- in phase 3
- 14
- first study started
- 2005
Keep track of what changes. Save the japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated) studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2010 (6)
| Year | Studies |
|---|---|
| 2005 | 5 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2010 | 6 |
| 2012 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 1
- Phase 3
- 14
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 3
Valneva Austria GmbH (15) · Medical University of Vienna (1) · Helsinki University Central Hospital (1) · Singapore General Hospital (1)
Often tested with
Tested in the same studies.
Hepatitis A Vaccines (1) · Japanese Encephalitis Vaccines (1)
Studies
Open first, then newest update. How each study uses japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated) is read from its arms, and is right about nine times in ten.
Testing it · 18
- An Experimental Medicine Decipher of a Minimum Correlate of Cellular ImmunityRecruitingPhase 2Singapore General HospitalNCT05568953Written as Ixiaro
- Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51CompletedPhase 3Valneva Austria GmbHNCT00594958Written as IC51
- Immunogenicity Study of the Japanese Encephalitis Vaccine IC51CompletedPhase 3Valneva Austria GmbHNCT00604708Written as IC51
- Safety and Tolerability of the Japanese Encephalitis Vaccine IC51CompletedPhase 3Valneva Austria GmbHNCT00605085Written as Japanese Encephalitis purified inactivated vaccine (IC51)
- Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric PopulationCompletedPhase 3Valneva Austria GmbHNCT01041573Written as IC51 Japanese Encephalitis
- Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic CountriesCompletedPhase 3Valneva Austria GmbHNCT01047839Written as IC51
- Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-StudyCompletedPhase 3Valneva Austria GmbHNCT01246479Written as IC51 has given in the parent study IC51-322
- Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis VaccineCompletedPhase 4Medical University of ViennaNCT01398540Written as IXIARO
- Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post FillingCompletedPhase 3Valneva Austria GmbHNCT00776230Written as IC51
- Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic CountryCompletedPhase 3Valneva Austria GmbHNCT01296360Written as IXIARO
- Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51CompletedPhase 3Valneva Austria GmbHNCT00595465Written as Japanese Encephalitis purified inactivated vaccine
- Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51CompletedPhase 3Valneva Austria GmbHNCT00595309Written as IC51
- Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440CompletedPhase 3Valneva Austria GmbHNCT00596271Written as IC51
- Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51CompletedPhase 3Valneva Austria GmbHNCT00595790Written as IC51
- Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51CompletedPhase 3Valneva Austria GmbHNCT00595270Written as IC51
- Immune Response in IXIARO Batch JEV09L37 Recipients Before and After RevaccinationWithdrawnPhase 1Valneva Austria GmbHNCT01559831Written as IXIARO
- This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly PopulationCompletedPhase 4Valneva Austria GmbHNCT01158599Written as IXIARO®
- Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese EncephalitisCompletedPhase 3Helsinki University Central HospitalNCT01386827Written as C) primary immunizations with Ixiaro
Given in every arm · 1 — japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated) is usual care beside what is tested
As the comparator · 1 — what is tested is compared with japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated)
Codes
What other systems call japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated) · ClinicalTrials.gg INT016389
- UNII (FDA) DZ854I04ZEJAPANESE ENCEPHALITIS VIRUS STRAIN SA 14-14-2 ANTIGEN (FORMALDEHYDE INACTIVATED)Confirmed FDA, Wikidata
- Wikidata Q28859737japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)Confirmed FDA, Wikidata
- NCI Thesaurus C75796Japanese Encephalitis Virus Strain SA 14-14-2 Antigen (Formaldehyde Inactivated)Confirmed FDA, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | DZ854I04ZE | JAPANESE ENCEPHALITIS VIRUS STRAIN SA 14-14-2 ANTIGEN (FORMALDEHYDE INACTIVATED) | Confirmed FDA, Wikidata |
| Wikidata | Q28859737 | japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) | Confirmed FDA, Wikidata |
| NCI Thesaurus | C75796 | Japanese Encephalitis Virus Strain SA 14-14-2 Antigen (Formaldehyde Inactivated) | Confirmed FDA, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.